FDA
-
-
-
-
-
-
-
Genmab A/S (GMAB) PT Lowered to $39 at H.C. Wainwright
-
-
-
-
-
-
-
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Ly
-
-
-
-
-
-
-
Genmab reports 92% outpatient dosing rate in lymphoma drug trial
-
-
-
-
-
-
-
Genmab's epcoritamab combo meets Phase 3 trial goals in lymphoma
-
-
-
-
-
-
-
Genmab Publishes 2024 Annual Report
-
-
-
-
-
-
-
Genmab A/S (GMAB) PT Raised to $47 at BTIG
-
-
-
-
-
-
-
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
-
324,764 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

